Quick answers
- What is Trihexyphenidyl hydrochloride used for?
- The FDA-approved label (Trihexyphenidyl Hydrochloride, Remedyrepack Inc., July 23, 2026) says: “This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Trihexyphenidyl hydrochloride have a boxed warning?
- No. None of the 12 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Trihexyphenidyl hydrochloride?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Trihexyphenidyl hydrochloride been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Trihexyphenidyl hydrochloride?
- 8 companies list prescription products of Trihexyphenidyl hydrochloride in the FDA NDC Directory, including Remedyrepack Inc., Natco Pharma Limited and Novitium Pharma LLC.
What Trihexyphenidyl hydrochloride is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. …
— FDA label: Trihexyphenidyl Hydrochloride, Remedyrepack Inc., effective July 23, 2026. Read the full label on DailyMed →
The FDA has 12 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 12 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet · Solution · Syrup |
|---|---|
| Route | Oral |
| Prescription products | 16 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| trihexyphenidyl hydrochloride 2 mg tablet | Generic | $0.0816 per tablet |
| trihexyphenidyl hydrochloride 5 mg tablet | Generic | $0.1185 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Remedyrepack Inc.5 products
- Natco Pharma Limited2 products
- Novitium Pharma LLC2 products
- Actavis Pharma, Inc.2 products
- Golden State Medical Supply, Inc.2 products
- PAI Holdings, LLC dba PAI Pharma1 product
- Chartwell RX, LLC1 product
- Akorn1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (6)
- ANDA084363Watson Labs · November 26, 1974
- ANDA084364Watson Labs · December 6, 1974
- ANDA040177Pharm Assoc · April 17, 1997
- ANDA040254Novitium Pharma · December 24, 1998
- ANDA040251Chartwell Rx · September 27, 1999
- ANDA091630Natco Pharma Ltd · November 17, 2010
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 905269, 905273, 905283 |
|---|---|
| SPL set ID of the quoted label | b60ef86c-b8b6-4530-baaf-d4671ce961af |
| FDA labels (SPL) | 12 |
| FDA applications | 6 ANDA |
| Active ingredients (FDA) | TRIHEXYPHENIDYL |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Trihexyphenidyl Hydrochloride, Remedyrepack Inc., effective July 23, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →